125 related articles for article (PubMed ID: 16123745)
1. The relative sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in antipsychotic drug trials.
Leucht S; Engel RR
Neuropsychopharmacology; 2006 Feb; 31(2):406-12. PubMed ID: 16123745
[TBL] [Abstract][Full Text] [Related]
2. Linking the PANSS, BPRS, and CGI: clinical implications.
Leucht S; Kane JM; Etschel E; Kissling W; Hamann J; Engel RR
Neuropsychopharmacology; 2006 Oct; 31(10):2318-25. PubMed ID: 16823384
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotic efficacy of the antidepressant trimipramine: a randomized, double-blind comparison with the phenothiazine perazine.
Bender S; Olbrich HM; Fischer W; Hornstein C; Schoene W; Falkai P; Haarmann C; Berger M; Gastpar M;
Pharmacopsychiatry; 2003; 36(2):61-9. PubMed ID: 12734763
[TBL] [Abstract][Full Text] [Related]
4. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
[TBL] [Abstract][Full Text] [Related]
5. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
Woods SW; Gueorguieva RV; Baker CB; Makuch RW
Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
[TBL] [Abstract][Full Text] [Related]
6. Positive symptoms are associated with clinicians' global impression in treatment-resistant schizophrenia.
Lee J; Fervaha G; Takeuchi H; Powell V; Remington G
J Clin Psychopharmacol; 2015 Jun; 35(3):237-41. PubMed ID: 25839337
[TBL] [Abstract][Full Text] [Related]
7. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial.
Assion HJ; Reinbold H; Lemanski S; Basilowski M; Juckel G
Pharmacopsychiatry; 2008 Jan; 41(1):24-8. PubMed ID: 18203048
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
9. Maintenance treatment for schizophrenia with quetiapine.
Buckley PF
Hum Psychopharmacol; 2004 Mar; 19(2):121-4. PubMed ID: 14994322
[TBL] [Abstract][Full Text] [Related]
10. Comparative remission rates of schizophrenic patients using various remission criteria.
Beitinger R; Lin J; Kissling W; Leucht S
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Oct; 32(7):1643-51. PubMed ID: 18616969
[TBL] [Abstract][Full Text] [Related]
11. Amisulpride: a review of its efficacy in schizophrenia.
Möller HJ
Acta Psychiatr Scand Suppl; 2000; 400():17-22. PubMed ID: 10823307
[TBL] [Abstract][Full Text] [Related]
12. On the concept of remission in schizophrenia.
Leucht S; Beitinger R; Kissling W
Psychopharmacology (Berl); 2007 Nov; 194(4):453-61. PubMed ID: 17618422
[TBL] [Abstract][Full Text] [Related]
13. Equipercentile linking of the BPRS and the PANSS.
Leucht S; Rothe P; Davis JM; Engel RR
Eur Neuropsychopharmacol; 2013 Aug; 23(8):956-9. PubMed ID: 23433639
[TBL] [Abstract][Full Text] [Related]
14. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.
Dolzan V; Serretti A; Mandelli L; Koprivsek J; Kastelic M; Plesnicar BK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1562-6. PubMed ID: 18573584
[TBL] [Abstract][Full Text] [Related]
15. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
Olié JP; Spina E; Murray S; Yang R
Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials.
Buckley PF
Curr Med Res Opin; 2004 Sep; 20(9):1357-63. PubMed ID: 15383183
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of Brief Psychiatric Rating Scale scores.
Leucht S; Kane JM; Kissling W; Hamann J; Etschel E; Engel R
Br J Psychiatry; 2005 Oct; 187():366-71. PubMed ID: 16199797
[TBL] [Abstract][Full Text] [Related]
18. Augmentation of clozapine with a second antipsychotic--a meta-analysis of randomized, placebo-controlled studies.
Taylor DM; Smith L
Acta Psychiatr Scand; 2009 Jun; 119(6):419-25. PubMed ID: 19245679
[TBL] [Abstract][Full Text] [Related]
19. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study.
Zimbroff D; Warrington L; Loebel A; Yang R; Siu C
Int Clin Psychopharmacol; 2007 Nov; 22(6):363-70. PubMed ID: 17917555
[TBL] [Abstract][Full Text] [Related]
20. Atypical neuroleptics in acute schizophrenia: a double-blind comparative study of remoxipride and haloperidol.
den Boer JA; Westenberg HG
Psychopharmacol Bull; 1990; 26(1):99-107. PubMed ID: 1973547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
